Main Menu

Ambrx Biopharma, Inc.

(NASDAQ GS: AMAM)

Rigrodsky Law, P.A. is investigating Ambrx Biopharma, Inc. (“Ambrx”) regarding possible breaches of fiduciary duties and other violations of law related to Ambrx’s agreement to be acquired by Johnson & Johnson. Under the terms of the agreement, Ambrx shareholders will receive $28.00 per share in cash.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 06/15/2024


* Indicates a required field.

Back to Page